Grippferon nasal spray is an effective and safe drug for the prevention and treatment of acute respiratory viral infections (ARI, SARS) and influenza.
The main active component of Grippferon is highly active recombinant interferon alpha-2b. The drug was registered on the territory of the Russian Federation and launched into mass production in 1999.
Grippferon positive effects:
- blocks the reproduction of all types of human respiratory viruses;
- high therapeutic efficacy;
- highly effective as an emergency prevention drug;
- reduces the number of complications in patients with acute respiratory infection by 60−70%;
- has no contraindications for compatibility with other drugs.
Clinical and experimental studies of Grippferon were conducted on 4450 subjects in 14 research and clinical centers in Russia and Ukraine.
It is allowed for use even for children below age of 1 y.o. (including newborns), pregnant women and in period of lactation.